| Literature DB >> 35177851 |
Chi Fung Willis Chow1,2, Xuanming Guo1, Pallavi Asthana1, Shuo Zhang3, Sheung Kin Ken Wong3, Samane Fallah1, Sijia Che1, Susma Gurung1, Zening Wang4, Ki Baek Lee4, Xin Ge4, Shiyang Yuan5, Haoyu Xu5, Jacque Pak Kan Ip5, Zhixin Jiang3, Lixiang Zhai1, Jiayan Wu1, Yijing Zhang1, Arun Kumar Mahato6, Mart Saarma6, Cheng Yuan Lin1,7, Hiu Yee Kwan1, Tao Huang1, Aiping Lyu1, Zhongjun Zhou3, Zhao-Xiang Bian8,9, Hoi Leong Xavier Wong10.
Abstract
GDNF-family receptor a-like (GFRAL) has been identified as the cognate receptor of growth/differentiation factor 15 (GDF15/MIC-1), considered a key signaling axis in energy homeostasis and body weight regulation. Currently, little is known about the physiological regulation of the GDF15-GFRAL signaling pathway. Here we show that membrane-bound matrix metalloproteinase 14 (MT1-MMP/MMP14) is an endogenous negative regulator of GFRAL in the context of obesity. Overnutrition-induced obesity increased MT1-MMP activation, which proteolytically inactivated GFRAL to suppress GDF15-GFRAL signaling, thus modulating the anorectic effects of the GDF15-GFRAL axis in vivo. Genetic ablation of MT1-MMP specifically in GFRAL+ neurons restored GFRAL expression, resulting in reduced weight gain, along with decreased food intake in obese mice. Conversely, depletion of GFRAL abolished the anti-obesity effects of MT1-MMP inhibition. MT1-MMP inhibition also potentiated GDF15 activity specifically in obese phenotypes. Our findings identify a negative regulator of GFRAL for the control of non-homeostatic body weight regulation, provide mechanistic insights into the regulation of GDF15 sensitivity, highlight negative regulators of the GDF15-GFRAL pathway as a therapeutic avenue against obesity and identify MT1-MMP as a promising target.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35177851 DOI: 10.1038/s42255-022-00529-5
Source DB: PubMed Journal: Nat Metab ISSN: 2522-5812